Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Published:2022-10 Issue: Volume:65 Page:172-178
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Sim Sung Hoon,Kim Jeong Eun,Kim Min Hwan,Park Yeon Hee,Kim Jee Hyun,Suh Koung Jin,Koh Su-Jin,Park Kyong Hwa,Kang Myoung Joo,Ahn Mi Sun,Lee Kyoung Eun,Kim Hee-Jun,Ahn Hee Kyung,Kim Han Jo,Park Keon Uk,Byun Jae Ho,Park Jin Hyun,Lee Gyeong-Won,Lee Keun Seok,Sohn Joohyuk,Jung Kyung Hae,Park In Hae^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference27 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J Clin,2021

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Current and future management of HER2-positive metastatic breast cancer;Martinez-Saez;JCO Oncol Pract,2021

4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers;Drug development & registration;2023-09-01

2. Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer;Scientific Reports;2023-06-19

3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer;ESMO Open;2023-06